


1764 #
B7-18-98
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF)
Moriarty, R.M.; Penmasta, R.;)
Guo, L.; Rao, M.S.;)
and Mehta, R.G.)
SERIAL NO.: 09/008,957)
FILED: Jan. 20, 1998)
TITLE: 1 α -HYDROXYVITAMIN D₅,)
ITS SYNTHESIS AND USE)
IN CANCER PREVENTION)
AND THERAPY)

Group No.

Examiner:



BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Submitted herewith on Form PTO-1449 is a listing of references known to applicants and/or their attorney in compliance with the requirements of 37 C.F.R. 1.56. Copies of the document(s) are also being submitted.

The following is a disclosure of certain references in accordance with 37 C.F.R. Section 1.97 for consideration by the Patent and Trademark Office in connection with the above-identified application:

Publication	Author(s)	Date
Prevention of Preneoplastic Mammary Lesion Development by a Novel Vitamin D Analogue, 1 α -Hydroxyvitamin D ₅ , <u>Journal of the National Cancer Institute</u> , Vol. 89, No. 3, pp. 212-218	Mehta, R.G.; Moriarty, R.M.; Mehta, R.R.; Penmasta, R.; Lazzaro, G.; Constantinou, A.; and Guo L.	February 5, 1997

Concise Explanation of the Relevance
Of the Above-Cited References


The Mehta et al. article is directed to the same compound and method of cancer prevention and therapy as is claimed in the present invention. Some of the authors of the Mehta et al. article are also named as inventors of the present invention. The date of the publication, February 5, 1997, is less than one year prior to the filing date of the present application (January 20, 1998), and less than one month prior to the priority date of February 25, 1997, the filing date of the provisional application (No. 60/039,106) upon which the present application is based.

* * * * *

The applicant seeks to have the above-identified reference(s) available in the record for both the Examiner and the public to see.

Applicant specifically reserves all rights of privilege and confidentiality with respect to the application. Submission of this document is not to be construed as a waiver of these rights. Submission of patents or other references is without admission that any has an effective date prior to applicant's effective date of invention.

Respectfully submitted,


Harold J. Fassnacht
Reg. No. 35,507

Attorney for Applicants

BULLWINKEL PARTNERS, LTD.
19 S. LaSalle Street - Suite 1300

Chicago, Illinois 60603-1493
Telephone: 312-201-0777

Dated: *April 20, 1998*